한국 폐경 여성에서 Sclerostin (SOST) 유전자 다형성과 골밀도 및 순환계 Osteoprotegerin (OPG)–용질성 Receptor Activator of NF-κB Ligand (sRANKL) 사이의 연관성
The Association between Single Nucleotide Polymorphisms of Sclerostin (SOST) Gene, Bone Mineral Density and Circulating Osteoprotegerin (OPG)–Soluble Receptor Activator of NF-κB Ligand (sRANKL) in Postmenopausal Korean Women
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To investigate the relationship between polymorphisms of sclerostin (SOST) gene and bone mineral density (BMD) in postmenopausal Korean women. Materials and Methods: The SOST rs865429 (g.5942C>T), rs17882143 (c.28G>A), rs10534024 (-1396TCC/Del) polymorphisms were analyzed by Taqman assay and direct DNA sequencing in 399 postmenopausal Korean women. Serum CrossLaps (CTX), bone alkaline phosphatase (BAP), osteocalcin, osteoprotegerin (OPG) and soluble receptor activator of NF-kB ligand (sRANKL) were measured by enzyme linked immunosorbent assay. The BMD at the lumbar spine (LS) and femoral neck (FN) were determined by dual energy X-ray absorptiometry, and in 311 postmenopausal women receiving hormone therapy (HT) BMD was also measured after HT of 1 year. Results: The SOST g.5942C>T and c.28G>A polymorphisms were not observed. No significant differences in adjusted BMD at LS and FN, prevalence for osteoporosis and serum levels of biochemical markers were noted among genotypes of the SOST-1396TCC/del polymorphism. A significant association was found between SOST-1396TCC/Del polymorphism and the annual percent changes of BMD at LS but not FN after HT. The Del/Del genotype showed a significant decrease in BMD after HT compared with other genotypes. Conclusions: The SOST-1396TCC/Del polymorphism affects an annual BMD change at LS after HT in postmenopausal Korean women.
Abstract
Objectives: To investigate the relationship between polymorphisms of sclerostin (SOST) gene and bone mineral density (BMD) in postmenopausal Korean women. Materials and Methods: The SOST rs865429 (g.5942C>T), rs17882143 (c.28G>A), rs10534024 (-1396TCC/Del) polymorphisms were analyzed by Taqman assay and direct DNA sequencing in 399 postmenopausal Korean women. Serum CrossLaps (CTX), bone alkaline phosphatase (BAP), osteocalcin, osteoprotegerin (OPG) and soluble receptor activator of NF-kB ligand (sRANKL) were measured by enzyme linked immunosorbent assay. The BMD at the lumbar spine (LS) and femoral neck (FN) were determined by dual energy X-ray absorptiometry, and in 311 postmenopausal women receiving hormone therapy (HT) BMD was also measured after HT of 1 year. Results: The SOST g.5942C>T and c.28G>A polymorphisms were not observed. No significant differences in adjusted BMD at LS and FN, prevalence for osteoporosis and serum levels of biochemical markers were noted among genotypes of the SOST-1396TCC/del polymorphism. A significant association was found between SOST-1396TCC/Del polymorphism and the annual percent changes of BMD at LS but not FN after HT. The Del/Del genotype showed a significant decrease in BMD after HT compared with other genotypes. Conclusions: The SOST-1396TCC/Del polymorphism affects an annual BMD change at LS after HT in postmenopausal Korean women.
참고문헌 (29)
- Kanis JA, "The diagnosis of osteoporosis", J Bone Miner Res, 9, pp.1137~1141 (1994)
- Gong G, "Association between bone mineral density and candidate genes in different ethnic populations and its implications", Calcif Tissue Int, 72, pp.113~123 (2003)
- Ralston SH, "Genetics of osteoporosis", Endocr Rev, 31, pp.629~662 (2010)
- Kim JG, "Association of vitamin D receptor and estrogen receptor gene polymorphisms with bone mass in postmenopausal Korean women", Menopause, 8, pp.222~228 (2001)
- Kim JG, "The relationship among serum insulin-like growth factor-I, insulin-like growth factor-I gene polymorphism, and bone mineral density in postmenopausal women in Korea", Am J Obstet Gynecol, 186, pp.345~350 (2002)
- Kim JG, "Association between vitamin D receptor gene haplotypes and bone mass in postmenopausal Korean women", Am J Obstet Gynecol, 189, pp.1234~1240 (2003)
- Hoeppner LH, "Wnt signaling as a therapeutic target for bone diseases", Expert Opin Ther Targets, 13, pp.485~496 (2009)
- Johnson ML, "The Wnt signaling pathway and bone metabolism", Curr Opin Rheumatol, 19, pp.376~382 (2007)
- Westendorf JJ, "Wnt signaling in osteoblasts and bone diseases", Gene, 341, pp.19~39 (2004)
- Ott SM, "Sclerostin and Wnt signaling--the pathway to bone strength", J Clin Endocrinol Metab, 90, pp.6741~6743 (2005)
- van Bezooijen RL, "SOST", sclerostin, an osteocyte-derived negative regulator of bone formation, 2005, pp.16, 319~327
- Valero C, "Relationship of sclerostin and secreted frizzled protein polymorphisms with bone mineral density: an association study with replication in postmenopausal women", Menopause, 18, pp.802~807 (2011)
- Uitterlinden AG, "Polymorphisms in the sclerosteosis", van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites, 2004, pp.75, 1032~1045
- Sims AM, "Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes", J Bone Miner Res, 23, pp.499~506 (2008)
- Huang QY, "The -9247 T", C polymorphism in the SOST upstream regulatory region that potentially affects C, Bone, pp.2009, 45[DOI]
- Komulainen M, "Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial", J Clin Endocrinol Metab, 84, pp.546~552 (1999)
- Komulainen M, "Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial", Osteoporosis Int, 11, pp.211~218 (2000)
- Kim JG, "Association of the calcitonin gene (CA) polymorphism with bone mass and bone responsiveness to hormone therapy in postmenopausal Korean women", Menopause, 10, pp.544~549 (2003)
- Piters E, "Association study of polymorphisms in the SOST gene region and parameters of bone strength and body composition in both young and elderly men: data from the Odense Androgen Study", Calcif Tissue Int, 90, pp.30~39 (2012)
- Ohnaka K, "Association of single nucleotide polymorphisms in secreted frizzledrelated protein 1 gene with bone mineral density in Japanese women", Geriatr Gerontol Int, 9, pp.304~309 (2009)
- 김훈, "Association between polymorphisms in Wnt signaling pathway genes and bone mineral density in postmenopausal Korean women", MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 17(5), pp.1064~1070 (2010), LIPPINCOTT WILLIAMS WILKINS
- Mencej-Bedrac S, "Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population", Calcif Tissue int, 85, pp.501~506 (2009)
- Balemans W, "Lack of association between the SOST gene and bone mineral density in perimenopausal women: analysis of five polymorphisms", Bone, 31, pp.515~519 (2002)
- Deng HW, "Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes", Hum Genet, 103, pp.576~585 (1998)
- Kurabayashi T, "Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women", Am JObstet Gynecol, 180, pp.1115~1120 (1999)
- Jonhston CC Jr, "Early menopausal changes in bone mass and sex steroids", J Clin Endocrinol, 61, pp.905~911 (1985)
- Spencer GJ, "Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro", J Cell Sci, 119, pp.1283~1296 (2006)
- Rogers A, "Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment", J Clin Endocrinol Metab, 90, pp.6323~6331 (2005)
- 전성욱, "기저 골밀도 및 이전 호르몬 치료 골반응에 따른 호르몬 치료 골반응", 대한폐경학회지, 18(1), pp.15~27 (2012), 대한폐경학회[DOI]